Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer which lacks expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Management of TNBC remains a major challenge for the physicians and the research community. The relatively poor survival of TNBC patients, particularly those with advanced or metastatic disease, has remained an unsolved clinical problem over the past decades. It is largely due to the aggressive biological behavior, inter-tumoral heterogeneity and unavailability of effective targets in TNBC. Therefore, it is urgent to identify biomarkers to better stratify outcome, together with novel therapeutic targets for treating different subtypes of TNBC.
This Research Topic highlights the need to find more meaningful TNBC biomarkers and druggable targets based on originality, importance and timeliness. Although the 5-year overall survival rate of early breast cancer is over 90%, many patients still undergo recurrence, metastasis and drug resistance even after standard treatment in clinical practice.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
• Identification and validation of clinically significant novel biomarkers to predict therapy response and prognosis of TNBCr;
• Data analysis and validation identifying novel features of TNBC to better guide future treatment;
• Underlying mechanisms of recurrence or metastasis of TNBC;
• Identification of druggable targets in TNBC and classified subgroups;
• Preclinical research translating molecular targets into clinical practice;
• Clinical trials illustrating response to therapy in TNBC;
• Population-based studies of clinical features of TNBC
To be considered for publication, studies must demonstrate the applicability of anticancer modalities on a minimum of two well-authenticated cancer cell lines. Studies consisting solely of in silico investigation without experimental or in situ validation to support conclusions are not in scope of this Research Topic.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer which lacks expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Management of TNBC remains a major challenge for the physicians and the research community. The relatively poor survival of TNBC patients, particularly those with advanced or metastatic disease, has remained an unsolved clinical problem over the past decades. It is largely due to the aggressive biological behavior, inter-tumoral heterogeneity and unavailability of effective targets in TNBC. Therefore, it is urgent to identify biomarkers to better stratify outcome, together with novel therapeutic targets for treating different subtypes of TNBC.
This Research Topic highlights the need to find more meaningful TNBC biomarkers and druggable targets based on originality, importance and timeliness. Although the 5-year overall survival rate of early breast cancer is over 90%, many patients still undergo recurrence, metastasis and drug resistance even after standard treatment in clinical practice.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
• Identification and validation of clinically significant novel biomarkers to predict therapy response and prognosis of TNBCr;
• Data analysis and validation identifying novel features of TNBC to better guide future treatment;
• Underlying mechanisms of recurrence or metastasis of TNBC;
• Identification of druggable targets in TNBC and classified subgroups;
• Preclinical research translating molecular targets into clinical practice;
• Clinical trials illustrating response to therapy in TNBC;
• Population-based studies of clinical features of TNBC
To be considered for publication, studies must demonstrate the applicability of anticancer modalities on a minimum of two well-authenticated cancer cell lines. Studies consisting solely of in silico investigation without experimental or in situ validation to support conclusions are not in scope of this Research Topic.
